Immunome: EMA validates marketing application for varegacestat in desmoid tumours
What happened? Immunome announced on 30 October 2026 that the European Medicines Agency (EMA) has validated its marketing authorisation application (MAA) for varegacestat, an investigational oral medicine taken once daily for adults with desmoid tumours — rare, non-cancerous but often painful and invasive growths of connective tissue. Validation confirms the application is complete and EMA will begin its review under the centralised procedure. The application is supported by the Phase 3 RINGSIDE trial, which met its primary endpoint and all key secondary endpoints: an 84% reduction in the risk of disease progression or death versus placebo (hazard ratio 0.16), an objective response rate of 56% versus 9%, and meaningful improvements in pain.
Why it matters: Desmoid tumours have limited treatment options, and varegacestat works by blocking gamma-secretase, an enzyme involved in the signalling pathway that drives these growths. The EMA validation follows FDA acceptance of Immunome's New Drug Application for the same indication, with a US decision date of 28 April 2027. If approved on both sides of the Atlantic, varegacestat would offer a new oral option for patients with progressing desmoid tumours.
Read more: BioSpace (Business Wire), 30 October 2026